Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675. (Q35142268)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675. (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

0 references

metastatic melanoma

1 reference

based on heuristic

inferred from title

Judith Salmon Kaur

10

object named as

Judith S Kaur

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Wendy K. Nevala

4

object named as

Wendy K Nevala

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Roxana S. Dronca

1

object named as

Roxana S Dronca

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

author name string

Jacob B Allred

2

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Domingo G Perez

3

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Elizabeth A T Lieser

5

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Michael Thompson

6

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

William J Maples

7

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Edward T Creagan

8

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Barbara A Pockaj

9

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Timothy D Moore

11

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Benjamin T Marchello

12

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Svetomir N Markovic

13

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

publication date

1 August 2014

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

American Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

37

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

369-376

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348017

13 July 2018

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348017

13 July 2018

Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348017

13 July 2018

The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348017

13 July 2018

Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348017

13 July 2018

Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348017

13 July 2018

CD40-induced signaling in human endothelial cells results in mTORC2- and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348017

13 July 2018

Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348017

13 July 2018

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348017

13 July 2018

Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348017

13 July 2018

mTOR is activated in the majority of malignant melanomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348017

13 July 2018

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348017

13 July 2018

Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348017

13 July 2018

Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348017

13 July 2018

CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotranplantation model.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348017

13 July 2018

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348017

13 July 2018

Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348017

13 July 2018

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348017

13 July 2018

Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348017

13 July 2018

Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348017

13 July 2018

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348017

13 July 2018

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348017

13 July 2018

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348017

13 July 2018

Placenta growth factor and vascular endothelial growth factor B and C expression in microvascular endothelial cells and pericytes. Implication in autocrine and paracrine regulation of angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348017

13 July 2018

Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348017

13 July 2018

Possible role of the multidrug resistance-associated protein (MRP) in chemoresistance of human melanoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348017

13 July 2018

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348017

27 September 2018

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348017

27 September 2018

Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348017

27 September 2018

Measuring Response in Solid Tumors: Comparison of RECIST and WHO Response Criteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348017

27 September 2018

Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348017

27 September 2018

Radiological measurement of breast cancer metastases to lung and liver: comparison between WHO (bidimensional) and RECIST (unidimensional) guidelines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348017

27 September 2018

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348017

27 September 2018

PTEN expression in normal skin, acquired melanocytic nevi, and cutaneous melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23357973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/23357973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts

1 reference

https://pubmed.ncbi.nlm.nih.gov/23357973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Akt takes center stage in angiogenesis signaling

1 reference

https://pubmed.ncbi.nlm.nih.gov/23357973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A statistical simulation study finds discordance between WHO criteria and RECIST guideline

1 reference

https://pubmed.ncbi.nlm.nih.gov/23357973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor response to chemotherapy: The validity and reproducibility of RECIST guidelines in NSCLC patients1

1 reference

https://pubmed.ncbi.nlm.nih.gov/23357973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23357973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1097/COC.0B013E31827B45D4

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35142268&oldid=1670610441"